NCT04503629已完成2 期
A Phase 2,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- The endoscopic healing rate of duodenal ulcers at week 4.
研究概览
简要总结
A phase 2,double-blinded, double dummy, parallel, positive drug, randomised controlled multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD, 40mg QD compared with rabeprazole 10mg QD in patients with duodenal ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years, male and female
- •Has endoscopic diagnosis of active duodenal ulcer(s) (A1 or A2 stage) within 7 days prior to randomization
- •1 or 2 ulcers, 3-15 mm in diameter.
- •Signed informed concent form
排除标准
- •Has malignancy ulcer or malignancy ulcer not excluded, compouned ulcer, stress ulcer, esophageal erosion and ulcer, reflux esophagitis, Zollinger-Ellison syndrome.
- •Has esophageal and gastric varices；
- •With severe compliaction, such as pyloric obstruction, bleeding (Forrest I, IIa and IIb) or perforation, and etc；
- •Has other gastrointestinal disease (e.g.gastric ulcer), or has history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)；
- •Has undergone surgical resection or partly resection of esophageal, stomach or duodenum；
- •Has used Proton Pump Inhibitors(PPIs) within 5 days prior to randomization, or continuous more than 3 days of use of Proton Pump Inhibitors within 2 weeks prior to randomization；
- •Has been treated with triple or quandruple Helicobacter pylori eradication therapy included PPIs within 28 days prior to randomization；
- •Current use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) which may induce ulcer or ulceric bleeding or continuous more than 3 days of use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) within 28 days prior to randomization；
- •Laboratory tests performed in screning stage revealed Alanine aminotransferase (ALT) or aspartate aminotransferase (AST): > 1.5 upper limit of normal (ULN);
- •Laboratory tests performed in screning stage revealed thyroid stimulating hormone (TSH)；
- •Woman in pregnancy or lactation period；
- •Plan for pregancy or not willing to contracept with reliable contraception method during study period and within 90 days after the final time of investigational drug administratio；
- •Have alcohol abuse or drug abuse 1 years prior to screening；
- •Has hypersensitivity or allergy to investigatory drug, comparatory drug or related supplements；
- •Has participated or been participating other clinical trials(non-interventional study is excluded)；
- •Has an uncotroled disease, such as has a history of significant central nervous system (CNS), cardiovascular, pulmonary, hepatic, renal, or mental or psychological disorders with drug treatment that,in the opinion of the investigator, would not be suitable for participating this clinical trial.
- •In the opinion of the investigator, the patients with other situation would not be suitable for participating this clinical trial.
研究组 & 干预措施
Anaprazole Sodium 20mg QD
Experimental
administered orally once every 30-60 minutes before breakfast for 4 weeks
干预措施: Anaprazole Sodium (Drug)
Anaprazole Sodium 40mg QD
Experimental
administered orally once every 30-60 minutes before breakfast for 4 weeks
干预措施: Anaprazole Sodium (Drug)
Rabeprazole sodium 10mg QD
Active Comparator
administered orally once every 30-60 minutes before breakfast for 4 weeks
干预措施: Rabeprazole sodium (Drug)
结局指标
主要结局
The endoscopic healing rate of duodenal ulcers at week 4.
时间窗: Treatment of 4 weeks
The endoscopic ulcer healing rate is defined as the percentage of patients with endoscopic ulcer healed evaluated by investigators.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux EsophagitisReflux EsophagitisEsophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesGastroesophageal RefluxEsophagitisNCT05604261Xuanzhu Biopharmaceutical Co., Ltd.156
Unknown
3 期
A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.Duodenal Ulcer，DUNCT04215653Sihuan Pharmaceutical Holdings Group Ltd.448
已完成
2 期
Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic PatientsDiabetic Peripheral Neuropathic PainNCT02345291Novaremed Ltd.88
招募中
2 期
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and ExerciseType 2 Diabetes Mellitus (T2DM)NCT06647550Hyundai Pharm160
已完成
2 期
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19SARS-CoV InfectionCOVID-19ARDSAcute Respiratory Distress SyndromeNCT04659109Acticor Biotech60